Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Tafro Syndrome without Pathological Evidence Consistent with Castleman Disease: A Subtype of Tafro or a Distinct Disease Entity?

Siyuan Li, Yuhan Gao, Yue Dang, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6298.

https://doi.org/10.1182/blood-2024-204501

Published: 2024

Journal Articles

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Siyuan Li, Yuhan Gao, Yue Dang, Long Chang, Kaini Shen, Huacong Cai, Danqing Zhao, Chong Wei, Jun Feng, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6292.

https://doi.org/10.1182/blood-2024-203586

Published: 2024

Journal Articles

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

Yuhan Gao, Siyuan Li, Yue Dang, Minghui Duan, Jian Li, Lu Zhang

Blood (2024) 144 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2024-204570

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Rituximab, Chidamide, and Zanubrutinib±CHOP Could be a Promising Regimen for Newly Diagnosed Double-Expressor DLBCL (DE DLBCL)

Zhiming Li, Peng Sun, Lu Zhang, Xiangjun Fu, Yirong Jiang, Zhi Guo, Panpan LIU, Yu Wang, Hang Yang, Kangming Huang

Blood (2024) 144 (Supplement 1): 7807.

https://doi.org/10.1182/blood-2024-202818

Published: 2024

Journal Articles

Potential Opportunity for Drug Discontinuation in Idiopathic Multicentric Castleman Disease: Evaluating the Efficacy of TCP Protocol

Yue Dang, Yuhan Gao, Siyuan Li, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6310.

https://doi.org/10.1182/blood-2024-206712

Published: 2024

Journal Articles

A Prospective Clinical Study of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Double Expression Diffuse Large B-Cell Lymphoma

Yingying Wu, Ao Zhang, Liling Zhang, Guohui Cui, Fang Liu, Zhichao Chen, Zhipeng Chen, Lu Zhang, Lin Liu, Wenjuan He, Yu Hu, Linghui Xia, Jun Fang

Blood (2024) 144 (Supplement 1): 6501.

https://doi.org/10.1182/blood-2024-202483

Published: 2024

Journal Articles

Quality of Life after Idiopathic Multicentric Castleman Disease in China: A Cross-Sectional, Multi-Center Survey of Patient Reported Outcome and Caregiver Reported Outcome

Jia Chen, Miaoyan Zhang, Yuhan Gao, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 7852.

https://doi.org/10.1182/blood-2024-210512

Published: 2024

Journal Articles

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 4855.

https://doi.org/10.1182/blood-2024-202870

Published: 2024

Journal Articles

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Lu Zhang, Xuefeng Wang, Dongmei Hu, Shijie Li, Mingshan Sun, Qian Liu, Huimin Feng, Minran Zhou, Chen Chunyan, Huan Zhou, Sai Ma

Blood (2024) 144 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2024-199484

Published: 2024

Journal Articles

Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation

Xu Ji, Rebecca Williamson Lewis, Tarun Jain, Lu Zhang, Sharon M. Castellino

Blood (2024) 144 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2024-205951

Published: 2024

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Journal Articles

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter

Blood (2023) 142 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2023-174749

Published: 2023

Journal Articles

Histone Methyltranferase SETD8 Stimulates Proliferation and Anti-Apoptotic Effect in Acute Myeloid Leukemia through Epigenetically Upregulation of CXCR4

Zelong Cui, Man Xu, Zhenxing Gao, Minran Zhou, Yue Fu, Huimin Feng, Lu Zhang, Chunyan Chen

Blood (2023) 142 (Supplement 1): 2754.

https://doi.org/10.1182/blood-2023-184524

Published: 2023

Journal Articles

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

Qi Zhang, He Li, Xuelan Chen, Fan Gu, Lanxin Zhang, Lu Zhang, Tong Chen, Qiang Chen, Wentong Meng, Yu Wu, Hong Chang, Ting Liu, Chong Chen, Hongbing Ma, Yu Liu

Blood (2023) 142 (17): 1494–1499.

https://doi.org/10.1182/blood.2023020619

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Hao Zhao, Miao-yan Zhang, Kai-ni Shen, Jun Feng, Xin-xin Cao, Ming-hui Duan, Dao-bin Zhou, Lu Zhang, Jian Li

Blood (2023) 141 (21): 2654–2657.

https://doi.org/10.1182/blood.2023020009

Published: 2023

Includes: Supplemental data

Journal Articles

Maintenance Therapy with Single-Agent Lenalidomide for POEMS Syndrome

Yanying Yu, Xuemin Gao, Hao Zhao, Anan Li, Hao Cai, Jun Feng, Lu Zhang, Xinxin Cao, Jian Li

Blood (2022) 140 (Supplement 1): 10118–10119.

https://doi.org/10.1182/blood-2022-158642

Published: 2022

Journal Articles

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

Miaoyan Zhang, Yan-Ying Yu, Xin-xin Cao, Dao-Bin Zhou, Jian Li, Lu Zhang

Blood (2022) 140 (Supplement 1): 11923–11924.

https://doi.org/10.1182/blood-2022-156572

Published: 2022

Journal Articles

A Prospective Study of Bortezomib, Cyclophosphamide and Dexamethasone in Newly-Diagnosed Idiopathic Multicentric Castleman's Disease

Hao Zhao, Miaoyan Zhang, Yanying Yu, Xinxin Cao, Dao-Bin Zhou, Lu Zhang, Jian Li

Blood (2022) 140 (Supplement 1): 4442–4443.

https://doi.org/10.1182/blood-2022-166349

Published: 2022

Journal Articles

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Yan Zhang, Wei Wang, Jian Li, Daobin Zhou, Wei Zhang, Danqing Zhao, Chong Wei, Lu Zhang, Xinxin Cao

Blood (2022) 140 (Supplement 1): 6608–6609.

https://doi.org/10.1182/blood-2022-165934

Published: 2022

NARROW

Tafro Syndrome without Pathological Evidence Consistent with Castleman Disease: A Subtype of Tafro or a Distinct Disease Entity?

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Rituximab, Chidamide, and Zanubrutinib±CHOP Could be a Promising Regimen for Newly Diagnosed Double-Expressor DLBCL (DE DLBCL)

Potential Opportunity for Drug Discontinuation in Idiopathic Multicentric Castleman Disease: Evaluating the Efficacy of TCP Protocol

A Prospective Clinical Study of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Double Expression Diffuse Large B-Cell Lymphoma

Quality of Life after Idiopathic Multicentric Castleman Disease in China: A Cross-Sectional, Multi-Center Survey of Patient Reported Outcome and Caregiver Reported Outcome

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Residential Economic and Racial Segregation Is Associated with Acuity and Severity of Pediatric Leukemia at Presentation

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Histone Methyltranferase SETD8 Stimulates Proliferation and Anti-Apoptotic Effect in Acute Myeloid Leukemia through Epigenetically Upregulation of CXCR4

Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Maintenance Therapy with Single-Agent Lenalidomide for POEMS Syndrome

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

A Prospective Study of Bortezomib, Cyclophosphamide and Dexamethasone in Newly-Diagnosed Idiopathic Multicentric Castleman's Disease

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only